Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium ketophenylpyruvate, often referred to by the translation "calcium ketate" in Chinese pharmaceutical contexts, is a calcium salt of the alpha-keto analog of the essential amino acid phenylalanine. It is an active pharmaceutical ingredient (API) manufactured by Nanjing Baijingyu Pharmaceutical for use in compound alpha-ketoacid tablets, which are indicated for the treatment of protein metabolism disorders associated with chronic kidney disease (CKD). The compound acts as a nitrogen-sparing precursor; upon ingestion, it undergoes transamination to form phenylalanine, a process that utilizes nitrogen from non-essential amino acids. This mechanism helps to reduce the production of urea and the overall nitrogenous waste load on the kidneys, thereby slowing the progression of renal dysfunction and alleviating uremic symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium ketophenylpyruvate.